 CARMIEL, Israel and BOSTON, Oct. 15, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group Chiesi Group, today announced the final dosing of the last patient in the phase III BALANCE clinical trial of pegunigalsidase alfa PRX102, or the BALANCE Study, for the proposed treatment of Fabry disease. 